FRIEDMAN PAUL A 4

What Happened
Paul A. Friedman, a director of Prelude Therapeutics, received a derivative equity award on 2026-06-09 covering 38,000 shares. The filing reports a $0.00 cash price for the grant (reported value $0), and the award is described in the footnote as an option award that will fully vest upon the earlier of the company's next annual meeting or the one-year anniversary of the grant date, subject to continued service.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (timely filing).
• Type: Derivative award (option) — Code A (grant/award).
• Shares/units: 38,000; reported cash price: $0.00; reported value: $0.
• Vesting: Fully vests upon earlier of (a) next annual stockholder meeting or (b) one-year anniversary of the grant, contingent on continued service (per footnote).
• Shares owned after transaction: Not specified in this filing.
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in the filing.

Context: This is a standard director equity award rather than an open-market buy or sale. Such grants are routine compensation to align directors with shareholder interests; the award does not represent an immediate cash purchase or sale and will only convert to vested shares if vesting conditions are met.